Clinical trial · Interventional
IORT Versus CCRT for Pancreatic Cancer
Intraoperative Radiotherapy (IORT) Versus Concurrent Chemoradiotherapy (CCRT) for Pancreatic Cancer
NCT02981641CI-TRIAL-00025004IVCPCunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to find the better radiation therapy between intraoperative radiotherapy (IORT) and concurrent chemoradiotherapy (CCRT).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer Stage IV | Malignant Pancreatic Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Concurrent chemotherapy | Drug | — | UNRESOLVED |
| Intraoperative radiotherapy (IORT) | Radiation | — | UNRESOLVED |
| Sequential chemotherapy | Drug | — | UNRESOLVED |
| Three dimensional conformal radiation therapy (3D-CRT) | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Intraoperative radiotherapy (IORT) Group
- description
- Radiotherapy (Total dose: 18\~22 Gy; Single dose: 18\~22 Gy; Frequency: 1) + Sequential chemotherapy
- interventionNames
- Radiation: Intraoperative radiotherapy (IORT)
- Drug: Sequential chemotherapy
- type
- EXPERIMENTAL
- label
- Concurrent Chemoradiotherapy (CCRT) Group
- description
- Three dimensional conformal radiation therapy (3D-CRT) (Total dose: 60 Gy; Single dose: 2 Gy; Frequency: 30) + Concurrent chemotherapy (Gemcitabine(GEM), 800 mg/m2 weekly on Day 1-21, Q28d; or S-1 orally, 400 mg/d, bid on Day 1-21, Q28d) + Sequential chemotherapy
- interventionNames
- Drug: Sequential chemotherapy
- Radiation: Three dimensional conformal radiation therapy (3D-CRT)
- Drug: Concurrent chemotherapy
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosed as locally advanced pancreatic cancer. * Cannot be treated by surgical resection. Exclusion Criteria: * Treated by chemotherapy or radiotherapy before. * With distant organ metastasis. * Cannot tolerate surgery (Intraoperative radiotherapy)
References
Publications (0)
Data not yet available
No reference posted for this study.